Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study
The application of ICIs showed encouraging efficacy with an acceptable safety profile, suggesting its potential as an additional therapeutic option for CUP patients. Identifying predictive markers for ICIs response remains essential to enhance therapeutic strategies in CUP management.
Authors
- Qiufan Zheng (ORCID: https://orcid.org/0000-0003-3752-8506)
- Anqi Hu (ORCID: https://orcid.org/0000-0003-2675-1251)
- Yunjie Huang (ORCID: https://orcid.org/0000-0003-0636-1256)
- Tinghua Gao
- Yanxia Shi (ORCID: https://orcid.org/0000-0002-5414-8049)
- Ditian Shu
- R.C. Chen
- Xin An (ORCID: https://orcid.org/0000-0003-0683-5511)
- Riqing Huang (ORCID: https://orcid.org/0000-0003-3618-9311)
- Meiting Chen (ORCID: https://orcid.org/0000-0002-7195-1300)
- Cong Xue (ORCID: https://orcid.org/0000-0003-3558-8572)
- Haifeng Li (ORCID: https://orcid.org/0000-0001-8541-279X)
- Zhousan Zheng
Institutions
- Sun Yat-sen University (CN)
- Central People's Hospital of Zhanjiang (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s00432-025-06261-3
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China